CMAJ:风湿性多肌痛增高了心脏病发作及卒中风险

2014-08-01 Elizabeth(编译) 睿医资讯

风湿性多肌痛(PMR)是老年人群中最为常见的炎症性风湿病,女性和男性的终身风险分别为2.4%和1.7%。7月28日在线发表于CMAJ杂志的一项研究指出,PMR患者的血管性事件发生风险比是对照人群的2.5倍,60岁以下患者风险最高。 来自英国初级保健关节炎研究中心(Arthritis Research UK Primary Care Centre)的Adam T. Ha

风湿性多肌痛(PMR)是老年人群中最为常见的炎症性风湿病,女性和男性的终身风险分别为2.4%和1.7%。7月28日在线发表于CMAJ杂志的一项研究指出,PMR患者的血管性事件发生风险比是对照人群的2.5倍,60岁以下患者风险最高。

来自英国初级保健关节炎研究中心(Arthritis Research UK Primary Care Centre)的Adam T. Hancock及其同事对3249例PMR患者及12 735例非PMR对照患者进行了比较,以明确PMR是否和其他炎症性风湿病类似,与血管性事件发生率增高相关。研究者们对患者进行了随访,直到患者发生首次血管性事件(心血管、脑血管或外周血管事件),所有患者的数据最多追踪至2011年5月的病例记录。

在对年龄、性别、已知血管危险因素进行校准后发现,PMR患者的血管性事件发生风险比非PMR患者更高,校准后的风险比(AHR)为2.6。PMR患者中的血管性事件发生率为36.1/人·年,而非PMR患者的发生率为12.2/人·年。

基于该研究结果,人们应增加对此类患者血管危险因素的关注。人们应考虑对PMR患者的血管危险因素进行积极管理以减少额外的风险。

该研究提示PMR与脑血管事件、心血管事件和外周血管事件间存在相关性,AHR分别为2.3、2.7和2.8。脑血管与心血管事件的发生风险在PMR诊断的最初6-12月内最高。50-59岁的患者血管性事件的发生风险增高幅度大于5倍;80岁及以上患者风险增高3倍。

PMR与血管性疾病相关的可能机制包括疾病的炎症负担、PMR与巨细胞动脉炎相关、长期应用皮质激素的影响。

原始出处:

Hancock AT, Mallen CD, Muller S, Belcher J, Roddy E, Helliwell T, Hider SL.Risk of vascular events in patients with polymyalgia rheumatica.CMAJ. 2014 Jul 28. pii: cmaj.140266. [Epub ahead of print]

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1281179, encodeId=3cce12811e984, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Sun Aug 03 01:30:00 CST 2014, time=2014-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561564, encodeId=09e31561564fd, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sun Aug 03 01:30:00 CST 2014, time=2014-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567573, encodeId=de61156e57389, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sun Aug 03 01:30:00 CST 2014, time=2014-08-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1281179, encodeId=3cce12811e984, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Sun Aug 03 01:30:00 CST 2014, time=2014-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561564, encodeId=09e31561564fd, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sun Aug 03 01:30:00 CST 2014, time=2014-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567573, encodeId=de61156e57389, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sun Aug 03 01:30:00 CST 2014, time=2014-08-03, status=1, ipAttribution=)]
    2014-08-03 liuxiaona
  3. [GetPortalCommentsPageByObjectIdResponse(id=1281179, encodeId=3cce12811e984, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Sun Aug 03 01:30:00 CST 2014, time=2014-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561564, encodeId=09e31561564fd, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sun Aug 03 01:30:00 CST 2014, time=2014-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567573, encodeId=de61156e57389, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sun Aug 03 01:30:00 CST 2014, time=2014-08-03, status=1, ipAttribution=)]
    2014-08-03 liuxiaona